Summary

Hidradenitis suppurativa (HS) is a chronic, inflam-matory skin condition characterized by painful nodules, abscesses, and fistulas in intertriginous areas. Immune-mediated inflammation is thought to be involved, necessitating early and appropriate therapy due to its significant impact on quality of life. Diagnosis relies on clinical examination, with staging systems aiding in severity assessment. Treatment options include topical and systemic medications like clindamycin and tetracyclines, as well as surgical interventions such as deroofing and excision. Biological agents, including anti-TNFs and anti-IL therapies, show promise in HS management. A multidisciplinary approach, combining various therapies tailored to each patient, is essential for optimal outcomes. Ongoing research into novel biologic therapies is crucial for improving treatment efficacy and patient well-being.